Logo 1 Logo 2

Clinical Trial Details

Trial ID: L5650
Source ID: NCT01030952
Associated Drug: Nateglinide
Title: Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion
Acronym:
Status: COMPLETED
Study Results: YES
Results: https://ClinicalTrials.gov/show/NCT01030952/results
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG: Nateglinide|DRUG: Acarbose
Outcome Measures: Primary: Change in Area Under Curve of 0-4 Hours Postprandial Glucose (AUCpp0-4hours) in Standardized Meal Test Using Continuous Glucose Monitoring System (CGMS), The postprandial glucose area under the curve (AUC)was calculated using values from the 3 time points. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. 0-4 hours AUC were calculated using trapezoid methods., 3 weeks (end of study) minus baseline | Secondary: Change in Incremental Glucose Peak (IGP) From Baseline, Incremental glucose peak (IGP) was the maximal incremental increase in blood glucose obtained at any point after meal, baseline, 3 weeks (end of study)|Change in Mean Blood Glucose (MBG), The 24 hour mean blood glucose (MBG) level was calculated as the mean of all the consecutive readings on baseline and end of study(3 weeks later) separately., baseline and at 3 weeks (end of study)|Change in Standard Deviation (SD) From Baseline of Mean Blood Glucose (MBG) Over 24 Hours., Change in standard deviation (SD) from baseline of mean blood glucose (MBG) describes the range of blood glucose fluctuation over 24 hours., baseline, 3 weeks (end of study)|Change in Mean of Daily Difference of Paired Blood Glucose Value (MODD), The mean of the daily differences (MODD), calculated as the average absolute difference of paired glucose values during two successive 24 hour periods, was used to assess day-to-day glycaemic variability., baseline, 3 weeks (end of study)|Changes in 24 Hour Glucose Area Under Curve (AUCpp), Blood samples were collected for measurement of plasma glucose at 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. The postprandial glucose area under the curve was calculated using values from the 4 time points. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM., baseline, end of study (3 weeks)|Change in Glycated Serum Albumin (GSA) Levels From Baseline After Treatment, GSA levels were to be determined by CGMS at 7:00\~10:00 am in the 4-hour standardized meal test before treatment after overnight fasting for efficacy assessments, baseline, 3 weeks (end of study)|Change in Insulin Levels (μU/ml) During Standardized Meal Test at Endpoint From Baseline, This outcome measure calculated the change in insulin levels between groups over time at 0, 30 then 120 minutes, baseline, 3 weeks (end of study)|Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C), change in LDL-C at 0, 30 and 120 minutes, baseline, 3 weeks (end of study)|Change of Total Cholesterol in Blood Lipids Levels During Standardized Meal Test at Endpoint From Baseline at Each Time Point, time to change in Total Cholesterol blood lipids level at 0, 30, 120 minutes, baseline, 3 weeks (end of study)|Change in Triglyceride (TG)Levels in Blood Lipid Levels During Standardized Meal Test at Endpoint, TG change in blood lipids level from baseline to endpoint, baseline, 3 weeks (end of study)|Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at the End of the Study, Blood samples were collected for measurement of HDL-C prior to (fasting) and 120 minutes following the start of a standardized meal test at Baseline and Week 3. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. HDL-C was assessed at each study site using the same method and same reference value., baseline, 3 weeks (end of study)|Change in Mean Amplitude of Glycaemic Excursion (MAGE), mean amplitude of glycaemic excursion (MAGE) is an average of the amplitudes of all glycemic excursions greater than a prespecified threshold size, baseline, 3 weeks (end of study)|The Percent of 24 Hour Hypoglycemic Measurements, Measures/compares changes in percentage of hypoglycemia(\<3.9mmol/l or \<70 mg/dl) in glucose measurements in 24hours by continuous glucose monitoring system (CGMS) at endpoint from baseline between groups. Reported values are percent change of the base absolute values \[100% \* ((X-Y)/Y)\], baseline, 3 weeks (end of study)|Change in Percent of 24 Hour Hyperglycemic Measurements, Measures/compares changes in percentage of hyperglycemia (\>7.8mmol/l or 140 mg/dl) in glucose measurements in 24 hours by continuous glucose monitoring system (CGMS) at endpoint from baseline between groups. Reported values are percent change of the base absolute values \[100% \* ((X-Y)/Y)\], baseline, 3 weeks (end of study)
Sponsor/Collaborators: Sponsor: Novartis Pharmaceuticals
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 103
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2009-12
Completion Date: 2011-02
Results First Posted: 2012-10-19
Last Update Posted: 2012-10-19
Locations: Sir Run Run Shaw Hospital, 3 East Qingchun Road, Hangzhou, 310016, China|Shanghai Tongji Hospital, 389 Xinchun Road, Shanghai, 200065, China|Shanghai Sixth People's Hospital, 600 Xuanshan Road, Shanghai, 200233, China
URL: https://clinicaltrials.gov/show/NCT01030952